Molecular imaging of hypoxia: Strategies for probe design and application

Current Organic Synthesis

Volumn 8, Issue 4, 2011, Pages 593-603

  Apte, Sandeep ^a   Chin, Frederick T ^a   Graves, Edward E ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Carbonic anhydrase ix; Copper 64; Fluorescence; Fluorination; Fluorine 18; HIF 1; Hypoxia; Molecular imaging; Positron emission tomography; Radiosynthesis; Single photon emission computed tomography

Indexed keywords

EID: 79959986431     PISSN: 15701794     EISSN: None     Source Type: Journal    
DOI: 10.2174/157017911796117179     Document Type: Article

References (82)

1. Thomlinson, R. H., Gray, L. H. The histological structure of some humanlung cancers and the possible implications for radiotherapy. Br. J. Cancer 1955, 9, 539-549.
2. Read, J. Mode of action of x-ray doses given with different oxygenconcentrations. Br. J. Radiol. 1952, 25, 651-661.
3. Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., Scott, O. C. A. The concentration of oxygen dissolved in tissues at the time of irradiation as afactor in radiotherapy. Br. J. Radiol. 1953, 26, 638-648.
4. Wright, E. A., Howard-Flanders, P. The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiol. 1957, 48, 26-32.
5. Höckel, M., Vaupel, P. Tumor Hypoxia, Definitions and Current Clinical,Biologic, and Molecular Aspects. J. Natl. Cancer Inst. 2001, 93, 266-276.
6. Brown, J. M., Wilson, W. R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
7. Teicher, B. A., Lazo, J. S., Sartorelli, A. C. Classification of antineoplasticagents by their selective toxicities toward oxygenated and hypoxic tumorcells. Cancer Res. 1981, 41, 73-81.
8. Teicher, B. A., Holden, S. A., al-Achi, A., Herman, T. S. Classification of antineoplastic treatments by their differential toxicity toward putativeoxygenated and hypoxic tumor subpopulations in vivo in the FSaII murinefibrosarcoma. Cancer Res. 1990, 50, 3339-3344.
9. Young, S. D., Marshall, R. S., Hill, R. P. Hypoxia induces DNAoverreplication and enhances metastatic potential of murine tumor cells. Proc. Natl. Acad. Sci. U. S. A. 1988, 85, 9533-9537.
10. Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., Dewhirst, M. W. Tumor oxygenation predicts for thelikelihood of distant metastases in human sof t tissue sarcoma. Cancer Res.1996, 56, 941-943.
11. Höckel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., Vaupel, P. Association between tumor hypoxia and malignant progression in advancedcancer of the uterine cervix. Cancer Res. 1996, 56, 4509-4915.
12. Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head andneck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38, 285-289.
13. Cuvier, C., Jang, A., Hill, R. P. Exposure to hypoxia, glucose starvation andacidosis: effect on invasive capacity of murine tumor cells and correlationwith cathepsin (L + B) secretion. Clin. Exp. Metastasis 1997, 15, 19-25.
14. Sundfor, K., Lyng, H., Rof stad, E. K. Tumour hypoxia and vascular densityas predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer 1998, 78, 822-827.
15. Höckel, M., Schlenger, K., Höckel, S., Vaupel, P. Hypoxic cervical cancerswith low apoptotic index are highly aggressive. Cancer Res. 1999, 59, 4525-4528.
16. Walenta, S., Wetterling, M., Lehrke, M., Schwickert, G., Sundfor, K., Rof stad, E. K., Mueller-Klieser, W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in humancervical cancers. Cancer Res. 2000, 60, 916-921.
17. Chan, D. A., Sutphin, P. D., Yen, S. E., Giaccia, A. J. Coordinate regulationof the oxygen-dependent degradation domains of hypoxia-inducible factor1a. Mol. Cell. Biol. 2005, 25, 6415-6426.
18. Birner, P., Gatterbauer, B., Oberhuber, G., Schindl, M., Rossler, K., Prodinger, A., Budka, H., Hainfellner, J. A. Expression of hypoxia-induciblefactor-1a in oligodendrogliomas: its impact on prognosis andneoangiogenesis. Cancer 2001, 92, 165-171.
19. Korkolopoulou, P., Patsouris, E., Konstantinidou, A. E., Pavlopoulos, P. M., Kavantzas, N., Boviatsis, E., Thymara, I., Perdiki, M., Thomas-Tsagli, E., Angelidakis, D., Rologis, D., Sakkas, D. Hypoxia-inducible factor1a/vascular endothelial growth factor axis in astrocytomas. Associations withmicrovessel morphometry, proliferation and prognosis. Neuropathol. Appl.Neurobiol. 2004, 30, 267-278.
20. Schindl, M., Schoppmann, S. F., Samonigg, H., Hausmaninger, H., Kwasny, W., Gnant, M., Jakesz, R., Kubista, E., Birner, P., Oberhuber, G. Overexpression of hypoxia-inducible factor 1a is associated with anunfavorable prognosis in lymph node-positive breast cancer. Clin. CancerRes. 2002, 8, 1831-1837.
21. Bos, R., van der Groep, P., Greijer, A. E., Shvarts, A., Meijer, S., Pinedo, H.M., Semenza, G. L., van Diest, P. J., van der Wall, E. Levels of hypoxiainduciblefactor-1a independently predict prognosis in patients with lymphnode negative breast carcinoma. Cancer 2003, 97, 1573-1581.
22. Dales, J. P., Garcia, S., Meunier-Carpentier, S., Andrac-Meyer, L., Haddad, O., Lavaut, M. N., Allasia, C., Bonnier, P., Charpin, C. Overexpression of hypoxia-inducible factor HIF-1a predicts early relapse in breast cancer:Retrospective study in a series of 745 patients. Int. J. Cancer 2005, 116, 734-739.
23. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitnecker, G., Oberhuber, G. Overexpression of hypoxia-inducible factor 1a is a marker for anunfavorable prognosis in early-stage cervical cancer. Cancer Res. 2000, 60,4693-4696.
24. Burri, P., Djonov, V., Aebersold, D. M., Lindel, K., Studer, U., Altermatt, H.J., Mazzucchelli, L., Greiner, R. H., Gruber, G. Significant correlation of hypoxia-inducible factor-1a with treatment outcome in cervical cancertreated with radical radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56,494-501.
25. Ishikawa, H., Sakurai, H., Hasegawa, M., Mitsuhashi, N., Takahashi, M., Masuda, N., Nakajima, M., Kitamoto, Y., Saitoh, J., Nakano, T. Expressionof hypoxia-inducible factor 1a predicts metastasis-free survival afterradiation therapy alone in stage IIIB cervical squamous cell carcinoma. Int. J.Radiat. Oncol. Biol. Phys. 2004, 60, 513-521.
26. Kimura, S., Kitadai, Y., Tanaka, S., Kuwai, T., Hihara, J., Yoshida, K., Toge, T., Chayama, K. Expression of hypoxia-inducible factor (HIF)-1a isassociated with vascular endothelial growth factor expression and tumorangiogenesis in human oesophageal squamous cell carcinoma. Eur. J.Cancer 2004, 40, 1904-1912.
27. Aebersold, D. M., Burri, P., Beer, K. T., Laissue, J., Djonov, V., Greiner, R.H., Semenza, G. L. Expression of hypoxia-inducible factor-1a: a novelpredictive and prognostic parameter in the radiotherapy of oropharyngealcancer. Cancer Res. 2001, 61, 2911-2916.
28. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K. C., Harris, A. L. Hypoxia-inducible factor (HIF1Aand HIF2A), angiogenesis, and chemoradiotherapy outcome of squamouscell head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002, 53, 1192-1202.
29. Sivridis, E., Giatromanolaki, A., Gatter, K. C., Harris, A. L., Koukourakis, M. I. Association of hypoxia-inducible factors 1a and 2a with activatedangiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002, 95, 1055-1063.
30. Semenza, G. L. Targeting HIF-1 for Cancer Therapy. Nat. Rev. Cancer 2003,3, 721-732.
31. Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.T., Chi, J. T., Jeffrey, S. S., Giaccia, A. J. Lysyl oxidase is essential forhypoxia-induced metastasis. Nature 2006, 440, 1222-1226.
32. Kallinowski, F., Zander, R., Höckel, M., Vaupel, P. Tumor tissueoxygenation as evaluated by computerized pO2-histography. Int. J. Radiat.Oncol. Biol. Phys. 1990, 19, 953-961.
33. Griffiths, J. R., Robinson, S. P. The OxyLite: a fibre-optic oxygen sensor. Br.J. Radiol. 1999, 72, 627-630.
34. Krohn, K. A., Link, J. M., Mason, R. P. Molecular imaging of hypoxia. J.Nucl. Med. 2008, 49, 129S-48S.
35. Nunn, A., Linder, K., Strauss, H. W. Nitroimidazoles and imaging hypoxia. Eur. J. Nucl. Med. 1995, 22, 265-280.
36. Martin, G. V., Cerqueira, M. D., Caldwell, J. H., Rasey, J. S., Embree, L., Krohn, K. A. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ. Res. 1990, 67, 240-4.
37. Minn, H., Gronroos, T. J., Komar, G., Eskola, O., Lehtio, K., Tuomela, J., Seppanen, M., Solin, O. Imaging of tumor hypoxia to predict treatmentsensitivity. Curr. Pharm. Des. 2008, 14, 2932-2942
38. Tatum, J. L., Kelloff, G. J., Gillies, R. J., Arbeit, J. M., Brown, J. M., Chao, K. S., Chapman, J. D., Eckelman, W. C., Fyles, A. W., Giaccia, A. J., Hill, R.P., Koch, C. J., Krishna, M. C., Krohn, K. A., Lewis, J. S., Mason, R. P., Melillo, G., Padhani, A. R., Powis, G., Rajendran, J. G., Reba, R., Robinson, S. P., Semenza, G. L., Swartz, H. M., Vaupel, P., Yang, D., Croft, B., Hof fman, J., Liu, G., Stone, H., Sullivan, D. Hypoxia: importance in tumorbiology, noninvasive measurement by imaging, and value of its measurementin the management of cancer therapy. Int. J. Radiat. Biol. 2006, 82, 699-757.
39. Chapman, J. D., Engelhardt, E. L., Stobbe, C. C., Schneider, R. F., Hanks, G.E. Measuring hypoxia and predicting tumor radioresistance with nuclearmedicine assays. Radiother. Oncol. 1998, 46, 229-237.
40. Arteel, G. E., Thurman, R. G., Yates, J. M., Raleigh, J. A. Evidence thathypoxia markers detect oxygen gradients in liver: pimonidazole andretrograde perfusion of rat liver. Br. J. Cancer 1995, 72, 889-895.
41. Evans, S. M., Jenkins, W. T., Joiner, B., Lord, E. M., Koch, C. J. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9Ls.c. tumors. Cancer Res. 1996, 56, 405-411.
42. Raleigh, J. A., Calkins-Adams, D. P., Rinker, L. H., Ballenger, C. A., Weissler, M. C., Fowler, W. C., Jr., Novotny, D. B., Varia, M. A. Hypoxiaand vascular endothelial growth factor expression in human squamous cellcarcinomas using pimonidazole as a hypoxia marker. Cancer Res. 1998, 58,3765-3768.
43. Russell, J., Carlin, S., Burke, S. A., Wen, B., Yang, K. M., Ling, C. C.Immunohistochemical detection of changes in tumor hypoxia. Int. J. Radiat.Oncol. Biol. Phys. 2009, 73, 1177-1186.
44. Cai, L., Lu, S., Pike, V. W. Chemistry with [18F]fluoride ion. Eur. J. Org.Chem. 2008, 2853-2873.
45. Chin, F. T., Morse, C. L., Shetty, H. U., Pike, V. W. Automatedradiosynthesis of [18F]SPA-RQ for imaging human brain NK1 receptorswith PET. J. Labelled Compd. Rad. 2006, 49, 17-31.
46. Block, D., Klatte, B., Knochel, A., Beckmann, R., Holm, U. No-carrieraddedfluorine-18-labeling of aliphatic compounds in high yields viaaminopolyether-supported nucleophilic substitution. J. Labelled Compd.Rad. 1986, 23, 467-477.
47. Briard, E., Zoghbi, S. S., Simeon, F. G., Imaizumi, M., Gourley, J. P., Shetty, H. U., Lu, S., Fujita, M., Innis, R. B., Pike, V. W. Single-Step High-YieldRadiosynthesis and Evaluation of a Sensitive 18F-Labeled Ligand forImaging Brain Peripheral Benzodiazepine Receptors with PET. J. Med.Chem. 2009, 52, 688-699.
48. Becaud, J., Mu, L., Karramkam, M., Schubiger, P. A., Ametamey, S. M., Graham, K., Stellfeld, T., Lehmann, L., Borkowski, S., Berndorff, D., Dinkelborg, L., Srinivasan, A., Smits, R., Koksch, B. Direct one-step 18Flabelingof peptides via nucleophilic aromatic substitution. Bioconjug. Chem.2009, 20, 2254-2261.
49. Lee, S. J., Oh, S. J., Chi, D. Y., Kil, H. S., Kim, E. N., Ryu, J. S., Moon, D.H. Simple and highly efficient synthesis of 3'-deoxy-3'-[18F]fluorothymidineusing nucleophilic fluorination catalyzed by protic solvent. Eur. J. Nucl.Med. Mol. Imaging 2007, 34, 1406-1409.
50. Mamat, C., Ramenda, T., Wuest, F. R. Recent applications of click chemistryfor the synthesis of radiotracers for molecular imaging. Mini Rev. Org.Chem. 2009, 6, 21-34.
51. Hwang, D. R., Dence, C. S., Bonasera, T. A., Welch, M. J. No-carrier-addedsynthesis of 3-[18F]fluoro-1-(2-nitro-1-imidazolyl)-2-propanol. A potentialPET agent for detecting hypoxic but viable tissues. Appl. Radiat. Isot. 1989,40, 117-126.
52. Kaemaeraeinen, E.-L., Kylloenen, T., Nihtilae, O., Bjoerk, H., Solin, O. Preparation of fluorine-18-labeled fluoromisonidazole using two differentsynthesis methods. J. Labelled Compd. Rad. 2004, 47, 37-45.
53. Adamsen, T. C. H., Grierson, J. R., Krohn, K. A. A new synthesis of thelabeling precursor for [18F]-fluoromisonidazole. J. Labelled Compd. Rad.2005, 48, 923-927.
54. Dolbier, W. R., Jr., Li, A. R., Koch, C. J., Shiue, C. Y., Kachur, A. V. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and anew fluorination procedure. Appl. Radiat. Isot. 2001, 54, 73-80.
55. Chin, F. T., Subbarayan, M., Sorger, J., Gambhir, S. S., Graves, E. E. Automated Radiosynthesis of [F-18]EF-5 for Imaging Hypoxia in Human. J.Labelled Compd. Rad. 2009, 52, S274.
56. Vavere, A. L., Lewis, J. S. Cu-ATSM: A radiopharmaceutical for the PETimaging of hypoxia. Dalton Trans. 2007, 4893-4902.
57. Gingras, B. A., Suprunchuk, T., Bayley, C. H. Preparation of somethiosemicarbazones and their copper complexes. III. Can. J. Chem. 1962, 40,1053-1059.
58. Bonnitcha, P. D., Vavere, A. L., Lewis, J. S., Dilworth, J. R. In vitro and invivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes forthe positron emission tomography imaging of hypoxia. J. Med. Chem. 2008,51, 2985-2991.
59. Nosco, D. L., Beaty-Nosco, J. A. Chemistry of technetiumradiopharmaceuticals 1: Chemistry behind the development of technetium-99m compounds to determine kidney function. Coordin. Chem. Rev. 1999,184, 91-123.
60. Cook, G. J., Houston, S., Barrington, S. F., Fogelman, I. Technetium-99mlabeledHL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.J. Nucl. Med. 1998, 39, 99-103.
61. Zhang, X., Melo, T., Ballinger, J. R., Rauth, A. M. Studies of 99mTc-BnAO(HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int. J.Radiat. Oncol. Biol. Phys. 1998, 42, 737-740.
62. Hodgkiss, R. J., Middleton, R. W., Parrick, J., Rami, H. K., Wardman, P., Wilson, G. D. Bioreductive fluorescent markers for hypoxic cells: a study of 2-nitroimidazoles with 1-substituents containing fluorescent, bridgeheadnitrogen,bicyclic systems. J. Med. Chem. 1992, 35, 1920-1926.
63. Liu, Y., Xu, Y., Qian, X., Liu, J., Shen, L., Li, J., Zhang, Y. Novelfluorescent markers for hypoxic cells of naphthalimides with twoheterocyclic side chains for bioreductive binding. Bioorg. Med. Chem. 2006,14, 2935-2941.
64. Nakata, E., Yukimachi, Y., Kariyazono, H., Im, S., Abe, C., Uto, Y., Maezawa, H., Hashimoto, T., Okamoto, Y., Hori, H. Design of abioreductively-activated fluorescent pH probe for tumor hypoxia imaging.Bioorg. Med. Chem. 2009, 17, 6952-6958.
65. Sobhanifar, S., Aquino-Parsons, C., Stanbridge, E. J., Olive, P. Reducedexpression of hypoxia-inducible factor-1a in perinecrotic regions of solidtumors. Cancer Res. 2005, 65, 7259-7266.
66. Oosterwijk, E., Ruiter, D. J., Hoedemaeker, P. J., Pauwels, E. K., Jonas, U., Zwartendijk, J., Warnaar, S. O. Monoclonal antibody G 250 recognizes adeterminant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 1986, 38, 489-494.
67. Pastoreková, S., Zavadova, Z., Kostal, M., Babusikova, O., Zavada, J. Anovel quasi-viral agent, MaTu, is a two-component system. Virology 1992,187, 620-626.
68. Velders, M. P., Litvinov, S. V., Warnaar, S. O., Gorter, A., Fleuren, G. J., Zurawski, V. R., Coney, L. R. New chimeric anti-pancarcinoma monoclonalantibody with superior cytotoxicity-mediating potency. Cancer Res. 1994,54, 1753-1759.
69. Brouwers, A., Verel, I., Van Eerd, J., Visser, G., Steffens, M., Oosterwijk, E., Corstens, F., Oyen, W., Van Dongen, G., Boerman, O. PETRadioimmunoscintigraphy of Renal Cell Cancer Using 89Zr-Labeled cG250Monoclonal Antibody in Nude Rats. Cancer Biother. Radiopharm. 2004, 19,155-163.
70. Divgi, C. R., O'Donoghue, J. A., Welt, S., O'Neel, J., Finn, R., Motzer, R. J., Jungbluth, A., Hof fman, E., Ritter, G., Larson, S. M., Old, L. J. Phase IClinical Trial with Fractionated Radioimmunotherapy using 131I-labeledChimeric G250 in Metastatic Renal Cancer. J. Nucl. Med. 2004, 45, 1412-1421.
71. Brouwers, A. H., Dörr, U., Lang, O., Boerman, O. C., Oyen, W. J. G., Steffens, M. G., Oosterwijk, E., Mergenthaler, H. G., Bihl, H., Corstens, F.H. M. 131I-cG250 monoclonal antibody immunoscintigraphy versus[18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: acomparative study. Nucl. Med. Commun. 2002, 23, 229-236.
72. Brouwers, A. H., Buijs, W. C. A. M., Mulders, P. F. A., de Mulder, P. H. M., van den Broek, W. J. M., Mala, C., Oosterwijk, E., Boerman, O. C., Corstens, F. H. M., Oyen, W. J. G. Radioimmunotherapy with [131I]cG250 inPatients with Metastasized Renal Cell Cancer: Dosimetric Analysis andImmunologic Response. Clin. Cancer Res. 2005, 11, 7178s-7186s.
73. Brouwers, A., Mulders, P., Oosterwijk, E., Buijs, W., Corstens, F., Boerman, O., Oyen, W. Pharmacokinetics and Tumor Targeting of 131I-Labeled F(ab')2Fragments of the Chimeric Monoclonal Antibody G250: Preclinical andClinical Pilot Studies. Cancer Biother. Radiopharm. 2004, 19, 466-477.
74. Chrastina, A., Závada, J., Parkkila, S., Kaluz, Š., Kaluzová, M., Rajcáni, J., Pastorek, J., Pastoreková, S. Biodistribution and Pharmacokinetics of 125IlabeledMonoclonal Antibody M75 Specific for Carbonic Anhydrase IX, anIntrinsic Marker of Hypoxia, in Nude Mice Xenografted with HumanColorectal Carcinoma. Int. J. Cancer 2003, 105, 873-881.
75. Thiry, A., Delayen, A., Goossens, L., Houssin, R., Ledecq, M., Frankart, A., Dogne, J.-M., Wouters, J., Supuran, C. T., Henichart, J.-P., Masereel, B. Synthesis and biological evaluation of a new family of antibenzylanilinosulfonamidesas CA IX inhibitors. Eur. J. Med. Chem. 2009,44, 511-518.
76. Thiry, A., Ledecq, M., Cecchi, A., Dogne, J. M., Wouters, J., Supuran, C. T., Masereel, B. Indanesulfonamides as carbonic anhydrase inhibitors. Towardstructure-based design of selective inhibitors of the tumor-associatedisozyme CA IX. J. Med. Chem. 2006, 49, 2743-2749.
77. Thiry, A., Ledecq, M., Cecchi, A., Frederick, R., Dogne, J.-M., Supuran, C.T., Wouters, J., Masereel, B. Ligand-based and structure-based virtualscreening to identify carbonic anhydrase IX inhibitors. Bioorg. Med. Chem.2009, 17, 553-557.
78. Abbate, F., Casini, A., Owa, T., Scozzafava, A., Supuran Claudiu, T. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent,potently inhibits cytosolic isozymes I and II, and transmembrane, tumorassociatedisozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 217-23.
79. Pastorekova, S., Casini, A., Scozzafava, A., Vullo, D., Pastorek, J., SupuranClaudiu, T. Carbonic anhydrase inhibitors: the first selective, membraneimpermeantinhibitors targeting the tumor-associated isozyme IX. Bioorg. Med. Chem. Lett. 2004, 14, 869-73.
80. Vullo, D., Scozzafava, A., Pastorekova, S., Pastorek, J., Supuran, C. T.Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IXwith fluorine-containing sulfonamides. The first subnanomolar CA IXinhibitor discovered. Bioorg. Med. Chem. Lett. 2004, 14, 2351-2356.
81. Zhang, L., Cecic, I., Cheng, Z., Gambhir, S. S., Graves, E. E. In 4th AnnualMeeting of the Society for Molecular Imaging Cologne, Germany, 2005.
82. Dubois, L., Lieuwes, N. G., Maresca, A., Thiry, A., Supuran, C. T., Scozzafava, A., Wouters, B. G., Lambin, P. Imaging of CA IX withfluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenatedcells in a xenograft tumour model. Radiother. Oncol. 2009, 92, 423-428.